The future is now: Using the lessons learned from the ACTIV COVID-19 therapeutics trials to create an inclusive and efficient clinical trials enterprise.

Autor: Adam SJ; Foundation for the National Institutes of Health, North Bethesda, USA., Dunsmore SE; National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, USA., Merck LH; Department of Emergency Medicine, Virginia Commonwealth University, Richmond, Virginia, USA., Read SW; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA., Rosenberg Y; National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA.
Jazyk: angličtina
Zdroj: Journal of clinical and translational science [J Clin Transl Sci] 2024 Oct 15; Vol. 8 (1), pp. e148. Date of Electronic Publication: 2024 Oct 15 (Print Publication: 2024).
DOI: 10.1017/cts.2024.622
Abstrakt: Competing Interests: The authors have no disclosures to make.
Databáze: MEDLINE